Current Report Filing (8-k)
November 20 2019 - 4:06PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
November 18, 2019
Date of Report (Date of earliest event reported)
AEVI GENOMIC
MEDICINE, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
1-35112
|
98-0217544
|
(State or other jurisdiction of
incorporation or organization)
|
(Commission File Number)
|
(I.R.S. Employer
Identification No.)
|
435 Devon Park Drive, Suite 715
Wayne, Pennsylvania 19087
(Address of principal executive offices,
zip code)
(610) 254-4201
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of exchange on which registered
|
Common stock, par value $0.0001 per share
|
GNMX
|
Nasdaq Capital Market
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or
Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 1.01. Entry Into
a Material Definitive Agreement.
On November 18, 2019,
Aevi Genomic Medicine, Inc. (the “Company”) entered into an agreement with The Children’s Hospital of Philadelphia
(“CHOP”) to extend the maturity date of that certain Secured Convertible Promissory Note dated as of March 29, 2019
(the “Note”), issued by the Company to CHOP in the original principal amount of $3,166,666.64 (the “Agreement”).
Pursuant to the Agreement, the maturity of the Note was extended until December 15, 2019, with an automatic further extension to
February 15, 2020, upon the occurrence of certain circumstances. In addition, pursuant to the Agreement, the principal amount of
the Note was increased to $4,354,166.63, and will increase to $4,749,999.96 on December 15, 2019 if the automatic extension is
triggered and to $5,145,833.29 if the Note is still outstanding on January 15, 2020.
The foregoing description
of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement,
a copy of which the Company expects to file as an exhibit to the Company’s Annual Report on Form 10-K for the year ending
December 31, 2019.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
AEVI GENOMIC MEDICINE, INC.
|
|
|
|
|
|
|
|
|
By:
|
/s/ Michael F. Cola
|
|
|
|
Name: Michael F. Cola
|
|
|
|
Title: President and Chief Executive Officer
|
|
Date: November 20, 2019
Aevi Genomic Medicine (NASDAQ:GNMX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aevi Genomic Medicine (NASDAQ:GNMX)
Historical Stock Chart
From Apr 2023 to Apr 2024